Buying guide

Maestro vs Johnson & Johnson Ottava in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Key differences

On DEPLOY's record, Johnson & Johnson Ottava is further along: at the commercial stage versus Maestro at the pilot stage, as of 2026.

Johnson & Johnson Ottava has more verified real-world deployments (3 vs 1).
Maestro is at the pilot stage; Johnson & Johnson Ottava at the commercial stage.

Attribute	No image on file Maestro View full model page →	Johnson & Johnson Ottava View full model page →
Manufacturer	Moon Surgical	Johnson & Johnson
Form factor	surgical	surgical
Maturity	pilot	commercial
Autonomy	◐ not independently verified	—
Availability	internal-onlyenterprise	internal-onlyenterprise
Price	$300,000-$800,000 (analyst estimate)	Not announced
Capability claims	Assists surgery (teleoperated-assisted, verified)	—
Brain	—	—
Verified deployments	1Moon Surgical	3
Privacy practices	—	—
Sources on file	9	4

Track this matchup

Get told the moment Maestro or Johnson & Johnson Ottava changes. Verified changes only, the second they are real. No press-release noise.

Maestro

Johnson & Johnson Ottava

Editorial summaries

Maestro

Moon Surgical's Maestro is a laparoscopic surgical-assistant platform (it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement system) and the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control.

On regulatory status (a correction worth recording): the Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan. As enterprise B2B surgical equipment, there is no consumer price.

Johnson & Johnson Ottava

J&J MedTech's Ottava is a soft-tissue general-surgery robotic platform with four arms integrated into the operating table, announced in 2020. It is pre-market: J&J submitted a De Novo request to the FDA in January 2026, and Ottava is not authorized to be marketed. DEPLOY classifies it research tier: J&J's corporate scale does not translate into verified surgical-robotics deployment, because the gating event (FDA clearance) has not occurred.

By the framework, Ottava sits at the same research tier as far smaller pre-market entrants. There is no price; it is not sold.

Common questions

How do Maestro and Johnson & Johnson Ottava differ?

On DEPLOY's record, Johnson & Johnson Ottava is further along: at the commercial stage versus Maestro at the pilot stage, as of 2026. Johnson & Johnson Ottava has more verified real-world deployments (3 vs 1). Maestro is at the pilot stage; Johnson & Johnson Ottava at the commercial stage.

What is the difference between Maestro and Johnson & Johnson Ottava?

Maestro and Johnson & Johnson Ottava are both surgical robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.

Is Maestro or Johnson & Johnson Ottava more autonomous?

On the DEPLOY registry, neither Maestro nor Johnson & Johnson Ottava has capabilities independently verified as fully autonomous yet; their recorded capabilities are teleoperated-assisted, demonstrated, or vendor-claimed. See the table for each capability's verification status.

Which has more verified deployments, Maestro or Johnson & Johnson Ottava?

Johnson & Johnson Ottava has more verified deployments (3) on the DEPLOY registry than Maestro (1). DEPLOY counts a deployment only when confirmed at a named site with a primary source.

Recent coverage

Escuelas del Condado Clark inician nuevo ciclo con enfoque en matemáticas y lecturaMaestro · The Nevada Independent · 2026-08-12
This Surgical Robot Could Transform the Operating RoomJohnson & Johnson Ottava · Bloomberg Technology · 2026-08-02
J&J’s robotics R&D head discusses Ottava’s folding arms, soothing sounds and haptics capabilityJohnson & Johnson Ottava · Medical Design & Outsourcing · 2026-07-31
Moon Surgical wins first FDA 510(k) clearance for surgical robotMaestro · Ben Smith, Deploy Editor · 2026-06-25

Related comparisons

Keep researching

Keep reading

All surgical robotsRegistry Every verified record in the category.MaestroModel The full model page.Johnson & Johnson OttavaModel The full model page.Moon SurgicalRecord The maker's verified record.Johnson & JohnsonRecord The maker's verified record.Versius vs MaestroCompare Another head-to-head.

Ask the registry

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.

Install instructions Download for Claude Desktop

Machine-readable: this page as markdown.

← Back to all consumer robots